| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/30/2009 | US20090111744 Human Growth Gene and Short Stature Gene Region |
| 04/30/2009 | US20090111743 Cysteine-branched heparin-binding growth factor analogs |
| 04/30/2009 | US20090111742 Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
| 04/30/2009 | US20090111741 Method for treating and/or preventing drug seeking behavior |
| 04/30/2009 | US20090111740 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
| 04/30/2009 | US20090111739 Sugar chain added glp-1 peptide |
| 04/30/2009 | US20090111738 Fibronectin polypeptides and methods of use |
| 04/30/2009 | US20090111737 Novel antibacterial agents |
| 04/30/2009 | US20090111736 Orally-Absorbed Solid Dose Formulation for Vancomycin |
| 04/30/2009 | US20090111735 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| 04/30/2009 | US20090111734 Compositions and methods for promoting hemostasis and other physiological activities |
| 04/30/2009 | US20090111733 Par-4 related methods and compositions |
| 04/30/2009 | US20090111732 Gelling Hydrophobic Injectable Polymer Compositions |
| 04/30/2009 | US20090111731 Novel topical application agents against mimic and age-related wrinkles |
| 04/30/2009 | US20090111160 fusion protein has trypsin and/or chymotrypsin loop being replaced with a vascular endothelial growth factor binding peptide; a culture product; anticarcinogenic agents, antitumor agents; antiinflammatory agent for treating cartilage and bone disorder; treating dermatitis |
| 04/30/2009 | US20090110756 Methods and Compositions Related to PLUNC Surfactant Polypeptides |
| 04/30/2009 | US20090110753 Enzyme-cleavable prodrug compounds |
| 04/30/2009 | US20090110744 Sustained release pharmaceutical compositions |
| 04/30/2009 | US20090110742 Long-acting colloidal insulin formulation and its preparation |
| 04/30/2009 | US20090110741 Method and compositions for polymer nanocarriers containing therapeutic molecules |
| 04/30/2009 | US20090110740 Materials and Methods for Modulating Metabolism |
| 04/30/2009 | US20090110735 Controlled release formulations |
| 04/30/2009 | US20090110734 Quaternised ammonium cyclodextrin compounds |
| 04/30/2009 | US20090110719 Polyamine modified particles |
| 04/30/2009 | US20090110711 Implantable device having a slow dissolving polymer |
| 04/30/2009 | US20090110710 Devices and methods for treating defects in the tissue of a living being |
| 04/30/2009 | US20090110694 Anti-Inflammatory Proteins and Improved Vaccines |
| 04/30/2009 | US20090110690 Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens |
| 04/30/2009 | US20090110687 Compositions and methods related to tim 3, a th1-specific cell surface molecule |
| 04/30/2009 | US20090110684 Neutralizing monoclonal antibodies to respiratory syncytial virus |
| 04/30/2009 | US20090110682 Antibody Having Inhibitory Effect on Amyloid Fibril Formation |
| 04/30/2009 | US20090110677 Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| 04/30/2009 | US20090110676 BAFF, Inhibitors Thereof and Their Use in the Modulation of B-Cell Response and Treatment of Autoimmune Disorders |
| 04/30/2009 | US20090110675 Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis |
| 04/30/2009 | US20090110674 Health supplement |
| 04/30/2009 | US20090110672 Angiogenic Tyrosyl tRNA Synthetase Compositions and Methods |
| 04/30/2009 | US20090110671 Agent for enhanching the production of collagen and it's use |
| 04/30/2009 | US20090110666 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours |
| 04/30/2009 | US20090110662 Modification of biological targeting groups for the treatment of cancer |
| 04/30/2009 | US20090110661 Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity |
| 04/30/2009 | US20090110660 for pancreatic cancer; intravenous infusion; Interleukin-2 (IL-2) |
| 04/30/2009 | US20090110659 Immunoglobulin specific to eotaxin for use in diagnosis, prevention and treatment of infections, autoimmune, inflammatory and allergic disorders; chemotactic cytokines designated human eotaxins; selectively modulate leukocyte function |
| 04/30/2009 | US20090110647 Method of preventing adverse effects by glp-1 |
| 04/30/2009 | US20090110644 Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| 04/30/2009 | US20090110638 Methods using the grueneberg ganglion chemosensory system |
| 04/30/2009 | US20090110637 LMP and Regulation of Tissue Growth |
| 04/30/2009 | US20090110632 Biological materials and uses thereof |
| 04/30/2009 | CA2704049A1 Means and methods for counteracting muscle disorders |
| 04/30/2009 | CA2703962A1 Oxidant resistant apolipoprotein a-1 and mimetic peptides |
| 04/30/2009 | CA2703947A1 Therapeutic and diagnostic methods using tim-3 |
| 04/30/2009 | CA2703614A1 Splice variants of gdnf and uses thereof |
| 04/30/2009 | CA2703544A1 Cytokine muteins |
| 04/30/2009 | CA2703493A1 A cell for use in production of heteroproteins and production method using the same |
| 04/30/2009 | CA2703370A1 Methods of treating urogenital-neurological disorders using modified clostridial toxins |
| 04/30/2009 | CA2703364A1 Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
| 04/30/2009 | CA2703350A1 Immune response inducer |
| 04/30/2009 | CA2703338A1 Method of preventing adverse effects by glp-1 |
| 04/30/2009 | CA2703234A1 Delivery of active agents |
| 04/30/2009 | CA2703184A1 Inhibition of urokinase-type plasminogen activator (upa) activity |
| 04/30/2009 | CA2702502A1 Sdf-1-based glycosaminoglycan antagonists and methods of using same |
| 04/30/2009 | CA2702333A1 Anti-ricin antibody |
| 04/30/2009 | CA2696160A1 Pegylation by the dock and lock (dnl) technique |
| 04/30/2009 | CA2695237A1 Anti-rantes antibodies and methods of use thereof |
| 04/30/2009 | CA2609172A1 Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| 04/29/2009 | EP2053409A1 Specific markers for metabolic syndrome |
| 04/29/2009 | EP2053135A1 Bone morphonic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| 04/29/2009 | EP2053061A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 04/29/2009 | EP2053060A1 SDF-1-based glyocosaminoglycan antagonists and methods of using same |
| 04/29/2009 | EP2052740A1 Crosslinked gelatin gel multilayered structure, carrier for bioactive factor, preparation for release of bioactive factor, and their production methods |
| 04/29/2009 | EP2052739A1 Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
| 04/29/2009 | EP2052738A1 THERAPEUTIC AGENT FOR ACCELERATION OF SPINAL NERVE REPAIR COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT |
| 04/29/2009 | EP2052736A1 Parathyroid hormone formulations und uses thereof |
| 04/29/2009 | EP2052735A1 Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood |
| 04/29/2009 | EP2052734A1 Proteins that stimulate the secretion of satiety hormones |
| 04/29/2009 | EP2052720A2 Use of at least one hydroxylamine compound for the treatment of eye disease |
| 04/29/2009 | EP2052716A1 Controlled release formulations |
| 04/29/2009 | EP2052713A2 Soluble FcgammaR fusion proteins and methods of use thereof |
| 04/29/2009 | EP2052340A2 Glycan data mining system |
| 04/29/2009 | EP2052085A2 Methods for modulating set and uses thereof |
| 04/29/2009 | EP2052081A1 Fusion proteins and methods for modulation of immune response |
| 04/29/2009 | EP2052076A1 Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8 |
| 04/29/2009 | EP2052011A1 Targeted polylysine dendrimer therapeutic agent |
| 04/29/2009 | EP2051995A1 Selective glucagon-like-peptide-2 (glp-2) analogues |
| 04/29/2009 | EP2051992A1 Method for producing condensation products from n-substituted glycine derivatives (peptoids) by sequential ugi-multicomponent reactions |
| 04/29/2009 | EP2051991A1 Cardioprotective compounds |
| 04/29/2009 | EP2051988A2 Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| 04/29/2009 | EP2051987A2 Use of cd83 in combination therapies |
| 04/29/2009 | EP2051736A2 Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
| 04/29/2009 | EP2051732A1 Methods of diagnosis and treatment for metabolic disorders |
| 04/29/2009 | EP2051731A1 Methods for reducing the incidence of mastitis |
| 04/29/2009 | EP2051730A2 Anti-h5n1 influenza activity of the antiviral protein cyanovirin |
| 04/29/2009 | EP2051729A2 Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatement of hormone-dependent cancers and corresponding pharmaceutical kits |
| 04/29/2009 | EP2051728A2 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
| 04/29/2009 | EP2051727A2 Methods for treating and limiting fibrotic disorders and keloids |
| 04/29/2009 | EP2051726A2 Methods for treating pain and screening analgesic compounds |
| 04/29/2009 | EP2051725A1 Methods of treating obesity using satiety factors |
| 04/29/2009 | EP2051719A1 Preparation with marine collagens for protease inhibition |
| 04/29/2009 | EP1976985A4 Methods and compositions related to mutant kunitz domain i of tfpi-2 |
| 04/29/2009 | EP1758935B1 High affinity telomerase t cell receptors |
| 04/29/2009 | EP1558269B1 Botulinum toxin formulations for oral administration |